{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:13:18Z","timestamp":1793196798531,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13555-025-01418-x","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T18:59:14Z","timestamp":1745521154000},"page":"1441-1453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post\u00a0Hoc Pooled Analysis of Two Phase\u00a03 Trials"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03308799","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03802344","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andreas","family":"Pinter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Freischl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"12","key":"1418_CR1","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1007\/s13555-023-01060-5","volume":"13","author":"PC Luna","year":"2023","unstructured":"Luna PC, Chu CY, Fatani M, et al. Psychosocial burden of psoriasis: a systematic literature review of depression among patients with psoriasis. Dermatol Ther (Heidelb). 2023;13(12):3043\u201355.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1418_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/ijd.14864","volume":"59","author":"S AlQassimi","year":"2020","unstructured":"AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis-comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566\u201371.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1418_CR3","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1080\/07853890.2021.1986637","volume":"53","author":"I Belinch\u00f3n Romero","year":"2021","unstructured":"Belinch\u00f3n Romero I, Dauden E, Ferr\u00e1ndiz Foraster C, Gonz\u00e1lez-Cantero \u00c1, Carrascosa Carrillo JM. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Ann Med. 2021;53(1):1727\u201336.","journal-title":"Ann Med"},{"issue":"5","key":"1418_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.17219\/acem\/69804","volume":"26","author":"A Bo\u017cek","year":"2017","unstructured":"Bo\u017cek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851\u20136.","journal-title":"Adv Clin Exp Med"},{"issue":"10","key":"1418_CR5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/jdv.13089","volume":"29","author":"IF Manalo","year":"2015","unstructured":"Manalo IF, Gilbert KE, Wu JJ. An updated survey for the 2007\u20132013 period of randomized controlled trials for psoriasis: treatment modalities, study designs, comparators, outcome measures and sponsorship. J Eur Acad Dermatol Venereol. 2015;29(10):1945\u201350.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1418_CR6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s13555-021-00544-6","volume":"11","author":"C Leonardi","year":"2021","unstructured":"Leonardi C, See K, Gallo G, et al. Psoriasis severity assessment combining physician and patient reported outcomes: the optimal psoriasis assessment tool. Dermatol Ther (Heidelb). 2021;11(4):1249\u201363.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1418_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060536","volume":"13","author":"M Augustin","year":"2023","unstructured":"Augustin M, Sommer R, Daud\u00e9n E, et al. Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase\u00a0IV, 1-cohort prospective observational study (the POSITIVE study). BMJ Open. 2023;13(2):e060536.","journal-title":"BMJ Open"},{"issue":"Suppl 2","key":"1418_CR8","doi-asserted-by":"publisher","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","volume":"64","author":"SR Feldman","year":"2005","unstructured":"Feldman SR, Krueger G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1418_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2011.01.022","volume":"66","author":"A Robinson","year":"2012","unstructured":"Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1418_CR10","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/jid.2009.391","volume":"130","author":"PI Spuls","year":"2010","unstructured":"Spuls PI, Lecluse LLA, Poulsen MLNF, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933\u201343.","journal-title":"J Invest Dermatol"},{"issue":"Suppl 2","key":"1418_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1468-3083.2009.03563.x","volume":"24","author":"V Bronsard","year":"2010","unstructured":"Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):17\u201322.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1418_CR12","first-page":"997","volume":"159","author":"MKA Basra","year":"2008","unstructured":"Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997\u20131035.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"1418_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.18761","volume":"37","author":"A Pinter","year":"2023","unstructured":"Pinter A, van de Kerkhof P. The role of topical therapies along the psoriasis patient journey: an overview from the Symposium \u201cTailoring topical psoriasis treatments to patients\u201d needs and expectations\u2019 of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(Suppl 1):3\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1418_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/1744666X.2020.1776116","volume":"16","author":"M Megna","year":"2020","unstructured":"Megna M, Cinelli E, Camela E, Fabbrocini G. Calcipotriol\/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Rev Clin Immunol. 2020;16(6):599\u2013620.","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"1418_CR15","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s13555-023-01003-0","volume":"13","author":"T Torres","year":"2023","unstructured":"Torres T, Galv\u00e1n J, Crutchley N, et al. Calcipotriol and betamethasone dipropionate cream based on PAD technology for the treatment of plaque psoriasis: a narrative review. Dermatol Ther (Heidelb). 2023;13(10):2153\u201369.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1418_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2023-2-8","volume":"12","author":"N Garc\u00eda","year":"2023","unstructured":"Garc\u00eda N, Guir\u00f3 P, Galv\u00e1n J, et al. Sensory properties analysis of a calcipotriol and betamethasone dipropionate cream vehicle formulated with an innovative PAD technology for the treatment of plaque psoriasis on the skin and scalp. Drugs Context. 2023;12:1\u20138.","journal-title":"Drugs Context"},{"issue":"11","key":"1418_CR17","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1111\/jdv.19330","volume":"37","author":"A Pinter","year":"2023","unstructured":"Pinter A, Reich A, Arenberger P, et al. Randomized phase\u00a03 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2023;37(11):2327\u201335.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1418_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.36849\/JDD.5653","volume":"20","author":"L Stein Gold","year":"2021","unstructured":"Stein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase\u00a03, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol. 2021;20(4):420\u20135.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1418_CR19","doi-asserted-by":"publisher","first-page":"2357618","DOI":"10.1080\/09546634.2024.2357618","volume":"35","author":"JL L\u00f3pez Estebaranz","year":"2024","unstructured":"L\u00f3pez Estebaranz JL, Kurzen H, Galv\u00e1n J. Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey. J Dermatolog Treat. 2024;35(1):2357618.","journal-title":"J Dermatolog Treat"},{"issue":"6977","key":"1418_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","volume":"310","author":"RJ Cook","year":"1995","unstructured":"Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452\u20134.","journal-title":"BMJ"},{"issue":"2","key":"1418_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/jdv.17734","volume":"36","author":"A Pinter","year":"2022","unstructured":"Pinter A, Green LJ, Selmer J, et al. A pooled analysis of randomized, controlled, phase\u00a03 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(2):228\u201336.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"13","key":"1418_CR22","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.3390\/jcm12134371","volume":"12","author":"D Baracaldo-Santamar\u00eda","year":"2023","unstructured":"Baracaldo-Santamar\u00eda D, Feliciano-Alfonso JE, Ramirez-Grueso R, Rojas-Rodr\u00edguez LC, Dominguez-Dominguez CA, Calderon-Ospina CA. Making sense of composite endpoints in clinical research. JCM. 2023;12(13):4371.","journal-title":"JCM"},{"key":"1418_CR23","first-page":"65","volume":"8","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Jones H, Mallbris L, et al. The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA. Psoriasis (Auckl). 2018;8:65\u201374.","journal-title":"Psoriasis (Auckl)"},{"issue":"1","key":"1418_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaad.2020.02.077","volume":"83","author":"LS Gold","year":"2020","unstructured":"Gold LS, Hansen JB, Patel D, Veverka KA, Strober B. PGAxBSA composite versus PASI: comparison across disease severities and as therapeutic response measure for Cal\/BD foam in plaque psoriasis. J Am Acad Dermatol. 2020;83(1):131\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"7491","key":"1418_CR25","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1136\/bmj.330.7491.594","volume":"330","author":"VM Montori","year":"2005","unstructured":"Montori VM, Permanyer-Miralda G, Ferreira-Gonz\u00e1lez I, et al. Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594\u20136.","journal-title":"BMJ"},{"issue":"5","key":"1418_CR26","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1418_CR27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","volume":"29","author":"G Carretero","year":"2018","unstructured":"Carretero G, Puig L, Carrascosa JM, et al. Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. J Dermatolog Treat. 2018;29(4):334\u201346.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1418_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09546634.2018.1544408","volume":"31","author":"TA Kouwenhoven","year":"2020","unstructured":"Kouwenhoven TA, van der Ploeg JAM, van de Kerkhof PCM. Treatment goals in psoriasis from a patient perspective: a qualitative study. J Dermatolog Treat. 2020;31(1):13\u20137.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"1418_CR29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ciresp.2021.10.003","volume":"100","author":"JM Enr\u00edquez-Navascu\u00e9s","year":"2022","unstructured":"Enr\u00edquez-Navascu\u00e9s JM, Aguirre-Allende I. Concept of risk factor as an estimate of association and treatment effect: measures and meaning. Cir Esp (Engl Ed). 2022;100(10):652\u20135.","journal-title":"Cir Esp (Engl Ed)"},{"issue":"4","key":"1418_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ad.2023.03.012","volume":"115","author":"A Gonz\u00e1lez-Dom\u00ednguez","year":"2024","unstructured":"Gonz\u00e1lez-Dom\u00ednguez A, Garc\u00eda-Agua N, Dauden E, Ventayol-Bosch P. The utility of long-term number needed to treat to evaluate interleukin 17 and 23 inhibitor therapies in the treatment of moderate to severe plaque psoriasis. Actas Dermosifiliogr. 2024;115(4):427\u20139.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"1418_CR31","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1007\/s12325-022-02065-w","volume":"39","author":"CL Leonardi","year":"2022","unstructured":"Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256\u201369.","journal-title":"Adv Ther"},{"key":"1418_CR32","first-page":"53","volume":"8","author":"R Ravasio","year":"2021","unstructured":"Ravasio R, Costanzo A, Antonelli S, Maiorino A, Losi S. Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Glob Reg Health Technol Assess. 2021;8:53\u20137.","journal-title":"Glob Reg Health Technol Assess"},{"issue":"5","key":"1418_CR33","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","volume":"152","author":"AY Finlay","year":"2005","unstructured":"Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861\u20137.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1418_CR34","first-page":"627","volume":"11","author":"L Salgado-Boquete","year":"2021","unstructured":"Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, Ruiz-Villaverde R, de la Cueva P, Belinch\u00f3n I. A new classification of the severity of psoriasis: what\u2019s moderate psoriasis? Life (Basel). 2021;11(7):627.","journal-title":"Life (Basel)"},{"issue":"34","key":"1418_CR35","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"H Kim","year":"2018","unstructured":"Kim H, Lee S, Kim J. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34):e214.","journal-title":"J Korean Med Sci"},{"key":"1418_CR36","doi-asserted-by":"publisher","unstructured":"Li RH, Belford GG. Instability of decision tree classification algorithms. In: Proceedings of the eighth ACM SIGKDD international conference on Knowledge discovery and data mining. Edmonton Alberta Canada: ACM; 2002. p. 570\u20135. https:\/\/doi.org\/10.1145\/775047.775131. Accessed 2 Apr 2025.","DOI":"10.1145\/775047.775131"},{"key":"1418_CR37","doi-asserted-by":"publisher","first-page":"5271091","DOI":"10.1155\/2017\/5271091","volume":"2017","author":"A Ott","year":"2017","unstructured":"Ott A, Hapfelmeier A. Nonparametric Subgroup Identification by PRIM and CART: a simulation and application study. Comput Math Methods Med. 2017;2017:5271091.","journal-title":"Comput Math Methods Med"},{"issue":"1","key":"1418_CR38","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s00403-025-04158-2","volume":"317","author":"VR Shaw","year":"2025","unstructured":"Shaw VR, Patel J, Varra V. Identifying transcriptomic predictors of brodalumab response in psoriasis using CART analysis. Arch Dermatol Res. 2025;317(1):638.","journal-title":"Arch Dermatol Res"},{"issue":"13","key":"1418_CR39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/1471-2164-13-472","volume":"12","author":"C Ainali","year":"2012","unstructured":"Ainali C, Valeyev N, Perera G, et al. Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics. 2012;12(13):472.","journal-title":"BMC Genomics"},{"key":"1418_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.meomic.2020.100001","volume":"1","author":"NQK Le","year":"2021","unstructured":"Le NQK, Do DT, Nguyen TTD, Nguyen NTK, Hung TNK, Trang NTT. Identification of gene expression signatures for psoriasis classification using machine learning techniques. Med Omics. 2021;1:100001.","journal-title":"Med Omics"},{"key":"1418_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104118","volume":"82","author":"P Achenbach","year":"2022","unstructured":"Achenbach P, Hippich M, Zapardiel-Gonzalo J, et al. A classification and regression tree analysis identifies subgroups of childhood type\u00a01 diabetes. EBioMedicine. 2022;82:104118.","journal-title":"EBioMedicine"},{"issue":"8","key":"1418_CR42","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s11606-020-05799-x","volume":"35","author":"EB Schroeder","year":"2020","unstructured":"Schroeder EB, Adams JL, Chonchol M, et al. Predictors of hyperkalemia and hypokalemia in individuals with diabetes: a classification and regression tree analysis. J Gen Intern Med. 2020;35(8):2321\u20138.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"1418_CR43","doi-asserted-by":"publisher","first-page":"1801943","DOI":"10.1183\/13993003.01943-2018","volume":"53","author":"PR Burgel","year":"2019","unstructured":"Burgel PR, Lemonnier L, Dehillotte C, et al. Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death. Eur Respir J. 2019;53(3):1801943.","journal-title":"Eur Respir J"},{"issue":"3","key":"1418_CR44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ygyno.2013.06.009","volume":"130","author":"JN Barlin","year":"2013","unstructured":"Barlin JN, Zhou Q, St Clair CM, et al. Classification and regression tree (CART) analysis of endometrial carcinoma: seeing the forest for the trees. Gynecol Oncol. 2013;130(3):452\u20136.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1418_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1245\/s10434-006-9145-2","volume":"14","author":"VA Valera","year":"2007","unstructured":"Valera VA, Walter BA, Yokoyama N, et al. Prognostic groups in colorectal carcinoma patients based on tumor cell proliferation and classification and regression tree (CART) survival analysis. Ann Surg Oncol. 2007;14(1):34\u201340.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1418_CR46","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/ajd.13624","volume":"62","author":"S Cheraghlou","year":"2021","unstructured":"Cheraghlou S, Sadda P, Agogo GO, Girardi M. A machine-learning modified CART algorithm informs Merkel cell carcinoma prognosis. Australas J Dermatol. 2021;62(3):323\u201330.","journal-title":"Australas J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01418-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01418-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T18:02:23Z","timestamp":1747764143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01418-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01418-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andreas Pinter has no conflicts of interest to declare. Jordi Galv\u00e1n is an employee of Almirall S.A. Frank Freischl\u00e4ger is co-founder and co-owner of Estimondo GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocols of the two phase\u00a03 studies were reviewed and approved by local institutional review boards or ethics committees (central institutional review board for trial MC2-01-C2: Quorum, 1501 Fourth Ave, Ste 800, Seattle, WA 98101; independent ethics committee for trial MC2-01-C7: Ethikkommission der \u00c4rztekammer, Hamburg, Weidestra\u00dfe 122b, 22083 Hamburg, Germany). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided written informed to participate in the phase\u00a03 studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}